Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer

Clinical Genitourinary Cancer

Volumn 14, Issue 1, 2016, Pages e1-e8

  Kwon, Young Suk ^a,b   Han, Christopher Sejong ^c   Yu, Ji Woong ^a,d   Kim, Sinae ^a,b   Modi, Parth ^c   Davis, Rachel ^c   Park, Ji Hae ^c   Lee, Paul ^a   Ha, Yun Sok ^e   Kim, Wun Jae ^f   Kim, Isaac Yi ^a,c  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d Sungkyunkwan University   (South Korea)

^e Kyungpook National University   (South Korea)

^f Chungbuk National University College of Medicine   (South Korea)

Author keywords

Active surveillance; Neutrophil to lymphocyte ratio; Pathological outcome; Prostate cancer; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL FEATURE; DISEASE MARKER; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; LOW RISK PATIENT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; PROSTATECTOMY; ROBOT ASSISTED SURGERY; BLOOD; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEUTROPHIL; PROSTATIC NEOPLASMS; TUMOR RECURRENCE;

DISEASE-FREE SURVIVAL; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEUTROPHILS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84952875787     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2015.07.018     Document Type: Article

References (30)

1. A.J. Templeton, M.G. McNamara, B. Šeruga, and et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis J Natl Cancer Inst 106 2014 dju124
2. S.I. Grivennikov, F.R. Greten, and M. Karin Immunity, inflammation, and cancer Cell 140 2010 883 899
3. D.S. O'Callaghan, D. O'Donnell, F. O'Connell, and K.J. O'Byrne The role of inflammation in the pathogenesis of non-small cell lung cancer J Thorac Oncol 5 2010 2024 2036
4. B.B. Aggarwal, R.V. Vijayalekshmi, and B. Sung Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe Clin Cancer Res 15 2009 425 430
5. S. Brandau, C.A. Dumitru, and S. Lang Protumor and antitumor functions of neutrophil granulocytes Semin Immunopathol 35 2013 163 176
6. H. Cho, H.W. Hur, S.W. Kim, and et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment Cancer Immunol Immunother 58 2009 15 23
7. M.J.M. Gooden, G.H. de Bock, N. Leffers, T. Daemen, and H.W. Nijman The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis Br J Cancer 105 2011 93 103
8. F. Imtiaz, K. Shafique, S.S. Mirza, Z. Ayoob, P. Vart, and S. Rao Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population Int Arch Med 5 2012 2
9. V. Kärjä, S. Aaltomaa, P. Lipponen, T. Isotalo, M. Talja, and R. Mokka Tumour-infiltrating lymphocytes: a prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy Anticancer Res 25 2005 4435 4438
10. S.R. Harlan, M.R. Cooperberg, E. Elkin, and et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE J Urol 170 2003 1804 1807
11. C.S. Han, J.S. Parihar, and I.Y. Kim Active surveillance in men with low-risk prostate cancer: current and future challenges Am J Clin Exp Urol 1 2013 72 82
12. A. Lopez-Farre, C. Caramelo, A. Esteban, and et al. Effects of aspirin on platelet-neutrophil interactions: role of nitric oxide and endothelin-1 Circulation 91 1995 2080 2088
13. J. Greenwood, and J.C. Mason Statins and the vascular endothelial inflammatory response Trends Immunol 28 2007 88 98
14. T.C. Alba-Loureiro, C.D. Munhoz, J.O. Martins, and et al. Neutrophil function and metabolism in individuals with diabetes mellitus Braz J Med Biol Res 40 2007 1037 1044
15. A.S. Deinard, and A.R. Page A study of steroid-induced granulocytosis in a patient with chronic benign neutropenia of childhood Br J Haematol 28 1974 333 345
16. D. Lorente, J. Mateo, A.J. Templeton, and et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use Ann Oncol 26 2014 750 755
17. H.K. Jensen, F. Donskov, N. Marcussen, M. Nordmark, F. Lundbeck, and H. von der Maase Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma J Clin Oncol 27 2009 4709 4717
18. F. Donskov Immunomonitoring and prognostic relevance of neutrophils in clinical trials Semin Cancer Biol 23 2013 200 207
19. K.S. Sfanos, and A.M. De Marzo Prostate cancer and inflammation: the evidence Histopathology 60 2012 199 215
20. S.I. McCash, and S. Marionneaux Epstein-Barr virus-associated lymphocytosis masquerading as lymphoma Blood 123 2014 1444
21. R. Kim, M. Emi, and K. Tanabe Cancer immunoediting from immune surveillance to immune escape Immunology 121 2007 1 14
22. V. Iremashvili, L. Pelaez, M. Manoharan, M. Jorda, D.L. Rosenberg, and M.S. Soloway Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols Eur Urol 62 2012 462 468
23. A. El Hajj, G. Ploussard, A. de la Taille, and et al. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS) BJU Int 111 2013 53 59
24. S. Jain, A. Loblaw, D. Vesprini, and et al. Gleason upgrading with time in a large prostate cancer active surveillance cohort J Urol 194 2015 79 84
25. G. Ploussard, L. Salomon, E. Xylinas, and et al. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance - does the risk of misclassification vary according to biopsy criteria? J Urol 183 2010 539 544
26. Y. Ohno, J. Nakashima, M. Ohori, T. Gondo, T. Hatano, and M. Tachibana Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma J Urol 187 2012 411 417
27. Y.H. Park, J.H. Ku, C. Kwak, and H.K. Kim Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy Springerplus 3 2014 243
28. D.C. McMillan The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer Cancer Treat Rev 39 2013 534 540
29. K. Shafique, M.J. Proctor, D.D. McMillan, and et al. The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients BMC Cancer 13 2013 292
30. N. Sadeghi, G.M. Badalato, G. Hruby, V. Grann, and J.M. McKiernan Does absolute neutrophil count predict high tumor grade in African-American men with prostate cancer? Prostate 72 2012 386 391